R. Hawkins

发表

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies

E. Pietsch, R. Swanson, R. Attar, 2015, Blood Cancer Journal.

The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery

R. Hawkins, S. Watkins, VV Mesyanzhinov, 1997, Gene Therapy.

Engineering a Cell-Penetrating Anti-HER2 Monoclonal Antibody for Efficient Delivery of Gold Nanoparticles into Cancer Cells To Enhance X-Ray Cancer Radiation Therapy

R. Hawkins, Kevin Guo, Bo-Sheng Wu, 2020 .

Retroviral transduction of human peripheral blood lymphocytes with bcl-xL promotes in vitro lymphocyte survival in pro-apoptotic conditions

D. Gilham, R. Hawkins, D. Eaton, 2002, Gene Therapy.

Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.

G. Batist, R. Whittom, M. Vincent, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC).

C. Sternberg, I. Davis, C. Szczylik, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibodies: from genes to targeted cancer gene therapy

R. Hawkins, S. Watkins, H. Whittington, 1998, Gene Therapy.

Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins

R. Hawkins, H. Whittington, L. Ashworth, 1998, Gene Therapy.

A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.

Sandra, S. Dunn, J. C. Barrett, 1998, Cancer research.

Efficient transgene regulation from a single tetracycline-controlled positive feedback regulatory system

R. Hawkins, S. A-Mohammadi, 1998, Gene Therapy.

Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line

J. Barrett, C. Afshari, G. Solomon, 2000, Breast Cancer Research.

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

J. Rossi, N. James, U. Prabhakar, 2010, British Journal of Cancer.

A phase II study of a 5 T 4 oncofoetal antigen tumour-targeted superantigen ( ABR-214936 ) therapy in patients with advanced renal cell carcinoma

G. Hedlund, J. Zweit, P. Stern, 2007 .

Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

K. Matthay, J. Courtier, Y. Mossé, 2015, British Journal of Cancer.

Title Phase I / II study of 131 I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma Permalink

K. Matthay, J. Courtier, Y. Mossé, 2015 .

Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.

C. Redfern, J. Carmichael, D. Cunningham, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues

R. Hawkins, L. Ashworth, L. Alvarez-Vallina, 1997, Gene Therapy.

A comparative study of intravenous versus intralymphatic interleukin-2, with assessment of effects of interleukin-2 on both peripheral blood and thoracic-duct lymph.

J. Fahey, B. Bonavida, H. Machleder, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.